clofibric acid has been researched along with Autoimmune Diabetes in 5 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to study the effect of adding polyunsaturated fatty acid (PUFA) n-3 or placebo (containing oleic acid) to a combined statin-fibrate treatment on plasma lipoproteins, lipoperoxidation, glucose homeostasis, total homocysteine (tHcy) and microalbuminuria (MA) in patients with diabetic dyslipidemia (DDL)." | 5.12 | N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. ( Písaríková, A; Stanková, B; Tvrzická, E; Vecka, M; Zák, A; Zeman, M, 2006) |
| "Etofibrate is a hypolipemic drug belonging to the fibrate class." | 2.69 | Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome. ( Chelstowski, K; Jastrzebska, M; Kopciewicz, J; Naruszewicz, M; Pieczul-Mróz, J; Torbus-Lisiecka, B, 1999) |
| "Adult patients with type 1 diabetes mellitus (n = 533; 256 men, 277 women; age: 35." | 1.35 | [Effectiveness of cardiometabolic risk reduction in patients with type 1 diabetes mellitus]. ( Fövényi, J; Gaál, Z; Gyimesi, A; Hídvégi, T; Hosszúfalusi, N; Jermendy, G; Nádas, J; Neuwirth, G; Oroszlán, T; Pánczél, P; Putz, Z; Vándorfi, G; Winkler, G; Wittmann, I, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nádas, J | 1 |
| Putz, Z | 1 |
| Fövényi, J | 1 |
| Gaál, Z | 1 |
| Gyimesi, A | 1 |
| Hídvégi, T | 1 |
| Hosszúfalusi, N | 1 |
| Neuwirth, G | 1 |
| Oroszlán, T | 1 |
| Pánczél, P | 1 |
| Vándorfi, G | 1 |
| Winkler, G | 1 |
| Wittmann, I | 1 |
| Jermendy, G | 1 |
| Candido, R | 1 |
| Zanetti, M | 1 |
| Zeman, M | 1 |
| Zák, A | 1 |
| Vecka, M | 1 |
| Tvrzická, E | 1 |
| Písaríková, A | 1 |
| Stanková, B | 1 |
| Geiss, HC | 1 |
| Parhofer, K | 1 |
| Jastrzebska, M | 1 |
| Torbus-Lisiecka, B | 1 |
| Pieczul-Mróz, J | 1 |
| Chelstowski, K | 1 |
| Kopciewicz, J | 1 |
| Naruszewicz, M | 1 |
1 review available for clofibric acid and Autoimmune Diabetes
| Article | Year |
|---|---|
Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Blood Coagulation Factors; Clofibric Acid | 2005 |
2 trials available for clofibric acid and Autoimmune Diabetes
| Article | Year |
|---|---|
N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination.
Topics: Adult; Albuminuria; Cholesterol Esters; Clofibric Acid; Diabetes Mellitus, Type 1; Dietary Supplemen | 2006 |
Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Diabetes Mellitus, Type 1; Factor VII; Fibrinogen; Humans; Hyperli | 1999 |
2 other studies available for clofibric acid and Autoimmune Diabetes
| Article | Year |
|---|---|
[Effectiveness of cardiometabolic risk reduction in patients with type 1 diabetes mellitus].
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Blood Pressure; Body Mass Inde | 2008 |
[Diabetic dyslipoproteinemia].
Topics: Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 1; Diabet | 2006 |